Navigation Links
Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection

/p>

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

       products or product candidates;

    -- the Company's ability to enter into and successfully execute license

       and collaborative agreements, if any;

    -- the adequacy of the Company's capital resources and cash flow

       projections, and the Company's ability to obtain sufficient financing

       to maintain the Company's planned operations;

    -- the adequacy of the Company's patents and proprietary rights;

    -- the impact of litigation that has been brought against the Company and

       its officers and directors and any proposed settlement of such

       litigation;

    -- the Company's ability to regain compliance with the NASDAQ's listing

       qualifications, or its ability to successfully appeal the NASDAQ

       delisting; and

    -- the other risks described under Certain Risks and Uncertainties Related

       to the Company's Business, as contained in the Company's Annual Report

       on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could ca
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/20/2009)... Reportlinker.com announces that a ...alogue. ,, Pipettes & Pipettors - A Global...er.com/p0164373/Pipettes--Pipettors---A-Global-Mar..._medium=pr&utm_campaign=prnewswire ,, Pip...t of any research laboratory. Large-scale applicat...
(Date:11/20/2009)... Reportlinker.com announces that a ...alogue. ,, Global Markets for Assisted Reprodu...r.com/p0164742/Global-Markets-for-Assisted-Reprodu...utm_medium=pr&utm_campaign=prnewswire ,, ...e U.S., 15 Countries in Europe and Japan. This rep...
(Date:11/20/2009)...Newswire-FirstCall/ -- Biotel Inc. (OTC Bulletin B...r ended September 30, 2009 with net earnings of $1... $3,263,000. This compares to net earnings of $32...$3,168,000 for the first quarter of last year. ,... President and CEO Steve Springrose said: "Biotel ...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2Linwood Group Research Suggests 3 Questions Everyone Should Ask When Choosing an Alcoholic Residential Centre 49149 1Linwood Group Research Suggests 3 Questions Everyone Should Ask When Choosing an Alcoholic Residential Centre 49149 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 1Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 3Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 1Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 2Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 3
...ces Deal for Vaccine Delivery System, NYON, Switze...metics Corporation announced today that the Compan... a non-human primate model.,Mucosal IgA antibodies...gainst infection by HIV. The data were presented b...c Officer in an,oral presentation, "Without Mucosa...
...rch 29, 2007 /PRNewswire-FirstCall/ -- Baxter,Inte...ta for its,adjuvant-free investigational pandemic ...se III clinical trial of the candidate,vaccine in .../II study indicated that Baxter,s H5N1 candidate,v...uces substantial,levels of cross immunity against ...
Other Medicine Technology:Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5
(Date:11/20/2009)... , , WASHINGTON, Nov. 20 /PRNewswire-USN...is urging senators to modify health care reform le...anguage regarding a health insurance individual co...ve and enforceable mandate will minimize adverse s...rating rules prescribed by the bill. ,, "The in...
(Date:11/20/2009)... , Senators and Congressm...Trouble Over their Health Care Vote , ...009 -- Senators and congressmen running for re-ele...by political guru Charlie Cook, may come to regret...lth care bill, according to a breaking Zogby Inter...
(Date:11/20/2009)... , , ST. LOUIS, Nov. 20 /PRNewswire-Fir...day announced that it will present at the Bank of ...e held December 2-3, 2009, at the Crowne Plaza Hot...ll present Wednesday, December 2nd at 8:30 a.m. Ea... may access a live, audio webcast of Centene,s pre...
(Date:11/20/2009)... , , LAS VEGAS, Nov. 20 /PRNewswire-USNewsw...rry, Executive Director of the Nevada Health Care ...tion (NHCA) commends and thanks Senate Majority Le...ation a step closer toward our goal of protecting ...rsing home care, and preserving the strength and v...
(Date:11/20/2009)... , Long durations of exposure to formaldehyde use...iated with an increased risk of death from myeloid...ne November 20 in the Journal of the National Can...cess mortality from lymphohematopoietic malignanci...nd funeral industry workers, all of whom may have ...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2
...ures Build Upon the Trusted Experience 100 Million...epend Upon, SAN FRANCISCO, July 14 BabyCenter, L...pectant parents around the world, announced,today ...d expert voice parents have depended on from BabyC...
...them return to prior playing level 83% of time, re...News) -- One of the country,s leading sports docto...sprained elbows in young athletes, a fact that ref...ting their arms at risk, said co-author Dr. E. Lyl...
..., July 14 Abaxis, Inc.,(Nasdaq: ABAX ), a medica...od analysis systems, has scheduled a conference ca...quarter of fiscal year 2009, ended June 30,2008. T... can listen via a live Internet web cast, which ca...
... Vical Incorporated,(Nasdaq: VICL ) today announ...n safety and immunogenicity data from a Phase 1 tr...pandemic influenza DNA vaccines on Thursday,July 1...y R. Smith, Ph.D., will,present preliminary safety...
... MS -- For the millions of junior,high, high schoo...tly, the,idea of returning to the classroom may be...wscom.com/cgi-bin/prnh/20080714/NYFNSP04 ), Whil...ing as hard to "fit in" as they do to improve thei...
...Monthly Fitness Program Promises to Take Beachbody...BEVERLY HILLS, Calif., July 14 In honor of his 50...er Tony Horton has released,the next in a long lin...ul fitness programs including Power,90(R), P90X(R)...
Other Medicine News:Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 2Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 3Health News:Elbow Injuries on Rise Among Young Athletes 2Health News:Elbow Injuries on Rise Among Young Athletes 3Health News:Abaxis to Report First Quarter Fiscal 2009 Financial Results Thursday, July 24, 2008 2Health News:Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines 2Health News:Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines 3Health News:Body Image is a Concern for Students of All Ages 2Health News:Beachbody(R) Launches One on One with Tony Horton 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: